Targeting the cancer epigenome for therapy (Q38821103)

6 September 2017

1 reference

title

Targeting the cancer epigenome for therapy (English)

1 reference

6 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Peter A Jones

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Stephen Baylin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

1 September 2016

1 reference

6 September 2017

Nature Reviews Genetics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

630-641

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrg.2016.93

31 May 2020

exact match

0 references

cites work

Histone core modifications regulating nucleosome structure and dynamics

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Integrative analysis of 111 reference human epigenomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The Cancer Genome Atlas Pan-Cancer analysis project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Cancer genetics and epigenetics: two sides of the same coin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

SWI/SNF chromatin remodeling complexes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Environmental exposures and mutational patterns of cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

5-Methylcytosine as an Endogenous Mutagen in the Human LDL Receptor and p53 Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Changes in DNA Methylation Patterns in Subjects Exposed to Low-Dose Benzene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation age of human tissues and cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Gene body methylation can alter gene expression and is a therapeutic target in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Histone deacetylase inhibitors as anti-neoplastic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Selective inhibition of tumor oncogenes by disruption of super-enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

IDH2 inhibition in AML: Finally progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

G9a, a multipotent regulator of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Targeting DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A decade of exploring the cancer epigenome - biological and translational implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Reactivating the expression of methylation silenced genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Genomic Classification of Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Current status of targeted therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Mutant BRAF melanomas--dependence and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic Therapeutics: A New Weapon in the War Against Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The future of epigenetic therapy in solid tumours--lessons from the past.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Methylation-induced repression--belts, braces, and chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation models histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Decitabine reactivated pathways in platinum resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic resensitization to platinum in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Combining Epigenetic and Immunotherapy to Combat Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic Modulators and the New Immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Cancer epigenetics: from mechanism to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Functions of DNA methylation: islands, start sites, gene bodies and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Effect of cytarabine and decitabine in combination in human leukemic cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.93

Augmenting antitumor immune responses with epigenetic modifying agents

31 March 2020

1 reference

12 December 2020

Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

1 reference

12 December 2020

New targets for hematologic malignancies

1 reference

12 December 2020

Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines

1 reference

12 December 2020

DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRG.2016.93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27629931%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 May 2020

1022900088

0 references

Fatcat ID

release_sl66llw6evfsfmuvjx4smnip5y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sl66llw6evfsfmuvjx4smnip5y

24 November 2022

mapped directly with Wikidata item

1 reference